News Allergan negotiates option to buy neurology biotech Allergan to co-develop Parkinson's drug with Lysosomal Therapeutics
News Biogen courts controversy with $750k-a-year rare disease dru... Biogen's SMA treatment approved - but price is $125,000 per dose
News Roche and AC Immune's Alzheimer's drug on right track Data suggest high dose used in phase 3 trial is most effective
News Amgen scores with new thyroid eye disease formulation Can Amgen's subcutaneous version of Tepezza inject renewed growth into the thyroid eye disease blockbuster?
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
